Kallikrein-thrombolytic and hypotensive action in cats--preliminary results.
An intravenous injection of kallikrein produced hypotensive and thrombolytic effects in anesthetized cats, using the blood superfused tendon technique. The thrombolytic action of kallikrein was mediated by an unstable substance. The generation of this substance was abolished by either acetylsalicylic acid (ASA) or aprotonin and enhanced by captopril. The hypotensive action of kallikrein was only partially inhibited by ASA. It is proposed that both these pharmacological effects of kallikrein are mediated by bradykinin which in turn releases prostacyclin from the endothelium. However, in contrast to the thrombolytic effect of kallikrein which is totally mediated by prostacyclin the hypotensive action of kallikrein depends not only on prostacyclin but also on another endothelium-derived vasorelaxant, e.g. EDRF.
Swies
J
J
Department of Pharmacology, N. Copernicus Academy of Medicine, Cracow.
Grodzińska
L
L
Sławiński
M
M
Gryglewski
R J
RJ
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D007611:Aprotinin / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology; D002415:Cats; D011464:Epoprostenol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D007275:Injections, Intravenous; D007610:Kallikreins / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male
D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents; D007611:Aprotinin; D002216:Captopril; D011464:Epoprostenol; D007610:Kallikreins; D001241:Aspirin